Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286455 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
NCT00286455: Completed Phase 3 study, sponsored by Takeda.
NCT00286455 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 329 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286455, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
Primary Outcome
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Interventions
- DRUG Placebo
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
What the finished NCT00286455 record still lists
NCT00286455 is an interventional study that assigns participants to a tested intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00286455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00286455 about?
NCT00286455 is a clinical study titled "Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
What is the current status of trial NCT00286455?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2006-02. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00286455?
The interventions under investigation include: Placebo (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00286455?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00286455's enrollment target sits among peer trials
329 1074th of 2000 higher than 927 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia